Education
About Us
Working with TipRanks
Follow Us
Mainz Biomed B.V. (MYNZ)
NASDAQ:MYNZ
Top Page
Mainz Biomed B.V.
(NASDAQ:MYNZ)
Rating:42Neutral
Price Target:―
Positive Factors
Clinical study progress
Mainz Biomed announced the enrollment of the first subject into the eAArly DETECT 2 clinical study in the US.
Collaborative agreements
An agreement with Quest Diagnostics has been signed for the ReconAAsense study with an option for commercialization.
Innovative detection technology
Mainz Biomed's Next Generation Test uses mRNA and FIT to enhance detection rates for advanced adenomas, showing improved results compared to industry standards.
Negative Factors
Analyst rating downgrade
Due to the company's current share price and market cap, the analyst believes it is prudent to downgrade the rating from Buy to Neutral without a price target.
Capital requirements
The company needs to raise a significant amount of capital to complete the eAArly DETECT 2 and a pivotal study before regulatory submission.
Financial challenges
Net loss totaled $11.0M in the first half of the year, with revenue being only $0.5M, indicating financial challenges.
Mainz Biomed B.V. (MYNZ) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.38M
Dividend YieldN/A
Average Volume (3M)238.03K
Price to Earnings (P/E)―
Beta (1Y)1.04
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees19
SectorHealthcare
Sector Strength43
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-65.57
Shares Outstanding3,038,853
10 Day Avg. Volume117,024
30 Day Avg. Volume238,032
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.48
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$14.00Price Target Upside566.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Mainz Biomed B.V. Business Overview & Revenue Model
Company DescriptionMainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
How the Company Makes MoneyMainz Biomed generates revenue through the sale of its proprietary diagnostic tests to healthcare providers, clinics, and laboratories. The company's primary revenue stream is derived from the commercialization of its flagship colorectal cancer screening test. Additionally, Mainz Biomed engages in strategic partnerships and collaborations with research institutions and healthcare organizations to enhance and expand its diagnostic offerings. These partnerships may contribute to revenue through joint development agreements, licensing deals, and the sharing of research findings that support product innovation and market expansion.
Mainz Biomed B.V. Financial Statement Overview
Summary
Mainz Biomed B.V. operates in the Medical Diagnostics & Screening industry and faces considerable financial difficulties. While there is some revenue growth and improvement in gross profit margin, the company is struggling with substantial losses and cash flow issues. The high leverage and low equity base pose additional risks, potentially impacting its financial health and operational sustainability.Income Statement
Mainz Biomed B.V. has shown some revenue growth over time; however, the company remains unprofitable with negative EBIT and net income consistently. The gross profit margin improved from previous years, but the net profit margin is substantially negative, indicating significant operational challenges.25
Negative
Balance Sheet
The company's balance sheet shows an improvement in stockholders' equity over the years, yet it remains highly leveraged with a rising debt-to-equity ratio. The equity ratio is very low, reflecting potential risks in financial stability.40
Negative
Cash Flow
The operating cash flow is persistently negative, and free cash flow has worsened over the years. The company faces significant challenges in generating cash from operations, which indicates potential liquidity issues.30
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 735.53K | 895.48K | 529.88K | 577.35K | 493.56K | 281.39K | Gross Profit |
| 359.29K | 509.66K | 182.15K | 177.62K | 123.08K | -61.27K | EBIT |
| -16.40M | -26.64M | -26.17M | -9.38M | -325.81K | -921.91K | EBITDA |
| -14.16M | -25.01M | -25.72M | -11.28M | -257.64K | -702.08K | Net Income Common Stockholders |
| -16.21M | -26.30M | -26.45M | -12.07M | -886.18K | -1.17M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 122.57K | 7.07M | 17.14M | 8.73M | 122.57K | 203.59K | Total Assets |
| 673.27K | 15.41M | 20.24M | 10.04M | 673.27K | 715.96K | Total Debt |
| 2.98M | 7.42M | 3.23M | 2.58M | 2.98M | 2.41M | Net Debt |
| 2.86M | 349.86K | -13.91M | -6.15M | 2.86M | 2.21M | Total Liabilities |
| 3.41M | 12.16M | 6.14M | 3.68M | 3.41M | 2.67M | Stockholders Equity |
| -2.74M | 3.25M | 14.10M | 6.36M | -2.74M | -1.95M |
| Cash Flow | Free Cash Flow | ||||
| -13.18M | -23.84M | -15.43M | -3.24M | -478.42K | -416.50K | Operating Cash Flow |
| -12.80M | -21.94M | -14.77M | -3.22M | -468.74K | -416.50K | Investing Cash Flow |
| -794.95K | -1.90M | -658.48K | 1.20M | -9.69K | 0.00 | Financing Cash Flow |
| 6.02M | 14.23M | 23.94M | 10.61M | 396.68K | 424.00K |
Mainz Biomed B.V. Technical Analysis
Negative
2.10
Price Trends
3.27
Negative
4.35
Negative
7.41
Negative
Market Momentum
-0.35
Positive
33.33
Neutral
21.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MYNZ, the sentiment is Negative. The current price of 2.1 is below the 20-day moving average (MA) of 2.67, below the 50-day MA of 3.27, and below the 200-day MA of 7.41, indicating a bearish trend. The MACD of -0.35 indicates Positive momentum. The RSI at 33.33 is Neutral, neither overbought nor oversold. The STOCH value of 21.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MYNZ.
Mainz Biomed B.V. Risk Analysis
Mainz Biomed B.V. disclosed 40 risk factors in its most recent earnings report. Mainz Biomed B.V. reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
Nasdaq maintains certain standards which Nasdaq requires listed companies meet for their respective securities to continue to be listed and traded on its exchange, and if we are unable to continue to meet such continued listing requirements, Nasdaq may choose to delist our ordinary shares from its exchange, which may adversely affect the liquidity and trading price of our ordinary shares. Q4, 2023
2.
We are subject to cybersecurity risks to operational systems, security systems, infrastructure and personal data processed by us or third-party vendors or suppliers and any material failure, weakness, interruption, cyber event, incident or breach of security could prevent us from effectively operating our business or subject us to liability for mishandling sensitive data. Q4, 2023
Mainz Biomed B.V. Peers Comparison
Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $14.74M | ― | -25.29% | ― | 26.67% | 44.02% | |
53 Neutral | $5.14B | 3.06 | -43.57% | 2.81% | 16.81% | -0.12% | |
49 Neutral | $8.91M | ― | -126.34% | ― | 3.87% | 35.37% | |
45 Neutral | $12.68M | ― | -127.82% | ― | -24.04% | 84.11% | |
42 Neutral | $6.38M | ― | -809.29% | ― | ― | ― | |
42 Neutral | $7.50M | ― | -290.85% | ― | 78.40% | 22.41% | |
35 Underperform | $13.75M | ― | 77.20% | ― | -3.76% | 39.52% |
* Healthcare Sector Average
Performance Comparison
MYNZ
Mainz Biomed B.V.
2.10
-20.77
-90.82%
TRIB
Trinity Biotech
0.74
-0.95
-56.21%
PRPO
Precipio
9.75
3.88
66.10%
BNGO
BioNano Genomics
3.77
-60.43
-94.13%
INBS
Intelligent Bio Solutions
1.29
-1.02
-44.16%
BIAF
bioAffinity Technologies, Inc.
0.28
-2.39
-89.51%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.